ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

ClinicalTrials.gov ID: NCT03873987

Public ClinicalTrials.gov record NCT03873987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label, PK and Safety Study to Evaluate the Relative Exposure and Safety of a New Formulation vs the Approved Formulation of a Single 1200 mg IV Dose of ORBACTIV® (Oritavancin) in Subjects Being Treated for ABSSSI

Study identification

NCT ID
NCT03873987
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Enrollment
102 participants

Conditions and interventions

Interventions

  • Current Formulation of Oritavancin Drug
  • Kimyrsa Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 15, 2019
Primary completion
Aug 26, 2019
Completion
Sep 3, 2019
Last update posted
Apr 12, 2021

2019

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
4
Facility City State ZIP Site status
ML-ORI-102 Study Site Chula Vista California 91911
ML-ORI-102 Study Site La Mesa California 91942
ML-ORI-102 Study Site Burr Ridge Illinois 60527
ML-ORI-102 Study Site Somers Point New Jersey 08244

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03873987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2021 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03873987 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →